Conquering Diseases

Study Of Chemotherapy For Children And Young Adults With High-Risk B-Cell Acute Lymphoblastic Leukemia (B-All)

Description

Children and young adults up to age 25 with High-Risk B-cell acute lymphoblastic leukemia (B-ALL) sought for a study of an investigational drug in combination of chemotherapy based on individual disease characteristics to improve 5-year disease-free survival (DFS).

Overview

Based on their disease characteristics, participants will receive either the standard chemotherapy or an combination of chemotherapy and an investigational to better understand how to improve treatment outcomes for children and young adults with newly diagnosed High-Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL).

What we're hoping for

To evaluate if an investigational combination of chemotherapy drugs improves outcomes in children and young adults with newly diagnosed High-Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL).

Additional Information

ClinicalTrials.gov Identifier: NCT03959085

 Principal Investigator

Stefanie  Lowas, MD

University of Massachusetts Medical School

 Study Contact

Danielle  Pichette-Patsky

+1 508-856-3077

Danielle.Pichette-Patsky@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989